At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02696 HENLIUS
Market Closed 03-21 16:08:23
30.500
-3.350
-9.90%
High33.800Low29.350Vol4.17M
Open33.800D1 Closing33.850Amplitude13.15%
Mkt Cap16.58BTradable Cap4.97BTotal Shares543.49M
T/O128.53MT/O Rate2.56%Tradable Shares163.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Alligator Bioscience Announces FDA Orphan Drug Designation For HLX22/AC101
Reuters  ·  03-20 14:12
Alligator Bioscience Announces FDA Orphan Drug Designation For HLX22/AC101
Shanghai Henlius Biotech Says Orphan-Drug Designation Granted By US FDA
Reuters  ·  03-19
Shanghai Henlius Biotech Says Orphan-Drug Designation Granted By US FDA
Shanghai Henlius Biotech - Orphan-Drug Designation of Hlx22 (Recombinant Humanized- Anti-Her2 Monoclonal Antibody Injection) Granted by US FDA
THOMSON REUTERS  ·  03-19
Shanghai Henlius Biotech - Orphan-Drug Designation of Hlx22 (Recombinant Humanized- Anti-Her2 Monoclonal Antibody Injection) Granted by US FDA
BRIEF-UBS Group's Long Position In H Shares Of Shanghai Henlius Biotech Increases To 7.55% - HKEX
Reuters  ·  02-19
BRIEF-UBS Group's Long Position In H Shares Of Shanghai Henlius Biotech Increases To 7.55% - HKEX
UBS Group's Long Position in H Shares of Shanghai Henlius Biotech Increases to 7.55% on Feb 13 From 5.43% - HKEX
THOMSON REUTERS  ·  02-19
UBS Group's Long Position in H Shares of Shanghai Henlius Biotech Increases to 7.55% on Feb 13 From 5.43% - HKEX
FDA Approves Shanghai Henlius Biotech's Investigational New Drug Application for Anti-Neurodegenerative Disease Drug
MT Newswires Live  ·  02-10
FDA Approves Shanghai Henlius Biotech's Investigational New Drug Application for Anti-Neurodegenerative Disease Drug
Henlius Doses First Patient in Esophagus Cancer Drug Phase 2 Trial in China
MT Newswires Live  ·  02-10
Henlius Doses First Patient in Esophagus Cancer Drug Phase 2 Trial in China
BRIEF-Shanghai Henlius Biotech's New Drug Application Of Innovative Small Molecular Hlx99 Approved By U.S. FDA
Reuters  ·  02-10
BRIEF-Shanghai Henlius Biotech's New Drug Application Of Innovative Small Molecular Hlx99 Approved By U.S. FDA
Shanghai Henlius Biotech Inc - Co's New Drug Application of Innovative Small Molecular Hlx99 ("Hlx99") Was Approved by U.S. FDA
THOMSON REUTERS  ·  02-10
Shanghai Henlius Biotech Inc - Co's New Drug Application of Innovative Small Molecular Hlx99 ("Hlx99") Was Approved by U.S. FDA
Henlius Biotech Strikes Licensing Deal with Dr. Reddy's for Myeloma Drug
MT Newswires Live  ·  02-07
Henlius Biotech Strikes Licensing Deal with Dr. Reddy's for Myeloma Drug
Stock Track | HENLIUS Soars 10.81% on Deal with Dr. Reddy's Labs for Myeloma Drug
Stock Track  ·  02-07
Stock Track | HENLIUS Soars 10.81% on Deal with Dr. Reddy's Labs for Myeloma Drug
BUZZ-Henlius soars on deal with India's Dr. Reddy's Labs for myeloma drug
Reuters  ·  02-07
BUZZ-Henlius soars on deal with India's Dr. Reddy's Labs for myeloma drug
Henlius: Co and DR. Reddy's Ink Licensing Deal for Hlx15 Expansion in Europe and U.S.
THOMSON REUTERS  ·  02-06
Henlius: Co and DR. Reddy's Ink Licensing Deal for Hlx15 Expansion in Europe and U.S.
BRIEF-Shanghai Henlius Biotech Says License Agreement With Dr. Reddy's For HLX15
Reuters  ·  02-06
BRIEF-Shanghai Henlius Biotech Says License Agreement With Dr. Reddy's For HLX15
Shanghai Henlius Biotech Inc - DR. Reddy's Shall Pay Company US$33 Mln
THOMSON REUTERS  ·  02-06
Shanghai Henlius Biotech Inc - DR. Reddy's Shall Pay Company US$33 Mln
Shanghai Henlius Biotech's Anti-Lung Cancer Injection Gets European Commission's Approval
MT Newswires Live  ·  02-06
Shanghai Henlius Biotech's Anti-Lung Cancer Injection Gets European Commission's Approval
BRIEF-Shanghai Henlius Biotech Says European Commission Approved Serplulimab Injection
Reuters  ·  02-05
BRIEF-Shanghai Henlius Biotech Says European Commission Approved Serplulimab Injection
BRIEF-Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Reuters  ·  02-05
BRIEF-Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (Es-Sclc)
THOMSON REUTERS  ·  02-05
Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (Es-Sclc)
Shanghai Henlius Biotech Inc - European Commission Approved Serplulimab Injection in Combination With Chemotherapy
THOMSON REUTERS  ·  02-05
Shanghai Henlius Biotech Inc - European Commission Approved Serplulimab Injection in Combination With Chemotherapy

Introduction

Company Name.
HENLIUS
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Company’s main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.
Issue price:
--
Invest in Global Markets with Tiger Brokers!
Open App